Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardio3 BioSciences Avoiding Binary Event Risks By Adding CAR-T Candidates

This article was originally published in The Pink Sheet Daily

Executive Summary

Belgium’s Cardio3 BioSciences aims to apply its experience in developing cell therapies, principally a stem cell therapy for heart failure that is in Phase III trials, to other therapeutic areas, reducing its exposure to the risks of a single success or failure event.

You may also be interested in...



Pipeline Watch: Ulcerative Colitis, COVID-19 Clinical Trial Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Synairgen Supercharges R&D With $100m Financing

With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.

Relief Therapeutics/NeuroRx's Aviptadil Promise In COVID-19-Associated Respiratory Failure

Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel